Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).


Options:
A: Arm Label: Bococizumab 150mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 150mg | Arm Label: Bococizumab 75mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 75mg | Arm Label: Bococizumab 150mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 150mg placebo | Arm Label: Bococizumab 75mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 75mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg; Assigned to Arm(s): Bococizumab 150mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg; Assigned to Arm(s): Bococizumab 75mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg placebo; Assigned to Arm(s): Bococizumab 150mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg placebo; Assigned to Arm(s): Bococizumab 75mg placebo
B: Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo (for Alirocumab) | Arm Label: Alirocumab 75/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Ezetimibe) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Ezetimibe); Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W
C: Arm Label: Alirocumab 75 mg/up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), Drug: alirocumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LMT (atorvastatin, simvastatin, or rosuvastatin); Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: alirocumab; Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo

Answer: C